SGMO - Sangamo Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.35
-0.90 (-5.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.25
Open16.20
Bid13.10 x 34100
Ask17.90 x 900
Day's Range15.20 - 16.27
52 Week Range9.70 - 27.50
Volume2,462,289
Avg. Volume2,119,320
Market Cap1.558B
Beta3.24
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.67
Trade prices are not sourced from all markets
  • What's Next for Spark Therapeutics
    Motley Fool23 hours ago

    What's Next for Spark Therapeutics

    This gene therapy biotech has its sights set on a second commercial-stage opportunity

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Fool3 days ago

    3 Biotech Stocks With Major Catalysts Incoming

    Clinical trial results and an FDA approval decision will move these three stocks in the weeks ahead.

  • PR Newswire6 days ago

    Sangamo Therapeutics Announces Presentation At The 2018 Wedbush PacGrow Healthcare Conference

    RICHMOND, Calif. , Aug. 10, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that management will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference ...

  • Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
    Market Realist7 days ago

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.

  • Why Sangamo Therapeutics, Inc. Stock Is Popping Today
    Motley Fool7 days ago

    Why Sangamo Therapeutics, Inc. Stock Is Popping Today

    The clinical-stage biotech reported encouraging news for its gene therapy targeting treatment of hemophilia A.

  • Benzinga7 days ago

    The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 8) AstraZeneca plc (ADR) (NYSE: AZN ) Bio-Rad Laboratories, Inc. ...

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: Nektar Therapeutics and Sangamo Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / U.S. equities were mixed on Wednesday as a result of disappointing corporate earnings combined with the latest trade news. The Dow Jones Industrial Average ...

  • Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
    Zacks7 days ago

    Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

    Sangamo (SGMO) delivered earnings and revenue surprises of -13.33% and -31.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire8 days ago

    Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A

    RICHMOND, Calif., Aug. 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced positive preliminary data from the Phase 1/2 clinical trial evaluating SB-525, a cDNA gene therapy candidate for Hemophilia A (the "Alta study"). SB-525 is being developed as part of a global collaboration between Sangamo and Pfizer Inc. for the development and commercialization of potential gene therapy programs for Hemophilia A. The Alta study is an open-label, dose-ranging clinical trial designed to assess the safety and tolerability of SB-525 in up to 20 adult subjects with severe Hemophilia A. To date, five patients have been treated at three dose levels.

  • PR Newswire8 days ago

    Sangamo Therapeutics Reports Second Quarter 2018 Financial Results

    Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial Evaluating SB-525 Gene Therapy for Hemophilia A Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time ...

  • Backed with $140M, startup launches three-pronged attack on liver diseases
    American City Business Journals8 days ago

    Backed with $140M, startup launches three-pronged attack on liver diseases

    Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker.

  • ACCESSWIRE8 days ago

    Sangamo Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Sangamo Therapeutics, Inc. (NASDAQ: SGMO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 5:00 PM Eastern ...

  • PR Newswire14 days ago

    Sangamo Therapeutics Announces Second Quarter 2018 Conference Call and Webcast

    RICHMOND, Calif. , Aug. 2, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the Company will release its second quarter 2018 financial results after the market closes ...

  • PR Newswire16 days ago

    Sangamo Announces Preliminary Data From Champions Study Evaluating SB-913, An Investigational Genome Editing Treatment For MPS II, To Be Presented September 5th At SSIEM 2018 Symposium

    RICHMOND, Calif., July 31, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that preliminary safety and efficacy data from the CHAMPIONS Study, a Phase 1/2 clinical trial ...

  • PR Newswire20 days ago

    Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.

    RICHMOND, Calif., July 27, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) announced today that the Company will host a webcast to review mucopolysaccharidosis Type II (MPS II, or Hunter syndrome) disease biology, standard of care treatment options, and scientific rationale for the development of SB-913, Sangamo's investigational in vivo genome editing treatment for MPS II. The webcast is scheduled for 2 p.m. Eastern Time on Wednesday, August 1, 2018. In late summer Sangamo plans to present preliminary data from the Phase 1/2 clinical trial evaluating SB-913 for MPS II ("the CHAMPIONS study"). This press release contains forward-looking statements regarding Sangamo's current expectations.

  • Benzinga24 days ago

    Sangamo Announces TxCell Acquisition, Patient Dosing In SB-318

    Sangamo Therapeutics Inc (NASDAQ: SGMO) announced Monday it would acquire TxCell for about €72 million to complement its ex vivo gene editing program. TxCell’s expertise in regulatory T-cell (Treg) development is meant to accelerate Sangamo’s clinical evaluation of CAR-Treg therapies to support organ transplants and treat autoimmune diseases like Crohn’s disease and multiple sclerosis. "We believe CAR-Treg therapies will prove to be as exciting for immunology as CAR-T has been for oncology,” Sangamo CEO Sandy Macrae said in a press release.

  • Options Traders Expect Huge Moves in Sangamo Therapeutics (SGMO) Stock
    Zacks24 days ago

    Options Traders Expect Huge Moves in Sangamo Therapeutics (SGMO) Stock

    Sangamo Therapeutics (SGMO) needs investors to pay close attention to the stock based on moves in the options market lately.

  • PR Newswire24 days ago

    Sangamo Therapeutics to Acquire TxCell

    RICHMOND, Calif. and VALBONNE, France, July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) and TxCell S.A. (TXCL.PA) announced today that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the contemplated acquisition of a majority stake of TxCell, file a simplified cash tender offer for the purchase of all then outstanding ordinary shares of TxCell, at a price of €2.58 per share in cash, or approximately €72 million, on a debt-free and cash-free basis. Subject to satisfaction of closing conditions (including in particular those relating to regulations governing foreign investments in France), Sangamo expects to complete the transaction in the fourth quarter of 2018.

  • PR Newswirelast month

    Sangamo Therapeutics Announces Technology Leadership Changes

    RICHMOND, Calif., July 13, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced that Michael Holmes, Ph.D., Senior Vice President and Chief Technology Officer, will resign from the Company effective July 20th to pursue an opportunity with a startup biotech company. Edward Rebar, Ph.D., has been named Senior Vice President and Chief Technology Officer, effective immediately. "We wish Michael well in his new endeavor," said Sandy Macrae, CEO of Sangamo.

  • ACCESSWIRElast month

    Stem Cell Companies Innovating For The Future

    HENDERSON, NV / ACCESSWIRE / July 12, 2018 / Many medical companies throughout the world are pinning their hopes for miracle cures on stem cell therapies. Because of the ability of stem cells to differentiate ...

  • Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far
    Motley Foollast month

    Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far

    The company's making progress, but competition could be fierce.

  • ACCESSWIRElast month

    Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks

    Stock Research Monitor: RXII, SAGE, and SGMO LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Endo International and Sangamo Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, ...

  • PR Newswire2 months ago

    Sangamo Therapeutics Appoints Karen Smith to its Board of Directors

    RICHMOND, Calif., June 28, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced the appointment of Dr. Karen Smith, an accomplished drug development executive, to the Company's Board of Directors. "Karen's extensive experience in drug development, registration and commercialization will benefit Sangamo tremendously, and I'm pleased to welcome her to our board," said Dr. Sandy Macrae, Chief Executive Officer of Sangamo. Dr. Smith has over 20 years of biopharmaceutical industry experience in the United States, Europe, Canada and Asia.

  • Why Sangamo Therapeutics and bluebird bio Slipped Lower Today
    Motley Fool2 months ago

    Why Sangamo Therapeutics and bluebird bio Slipped Lower Today

    Data from a competitor puts pressure on both biotechs' sickle cell programs